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Introduction: The combination of Adenosine (A), lidocaine (L) and Mg2+ (M) (ALM) has demonstrated
cardioprotective and resuscitative properties in models of cardiac arrest and hemorrhagic shock. This study
evaluates whether ALM also demonstrates organ protective properties in an endotoxemic porcine model.
Methods: Pigs (37 to 42 kg) were randomized into: 1) Control (n = 8) or 2) ALM (n = 8) followed by lipopolysaccharide
infusion (1 μg∙kg-1∙h-1) for five hours. ALM treatment consisted of 1) a high dose bolus (A (0.82 mg/kg), L (1.76 mg/kg),
M (0.92 mg/kg)), 2) one hour continuous infusion (A (300 μg∙kg-1 ∙min-1), L (600 μg∙kg-1 ∙min-1), M (336 μg∙kg-1 ∙min-1))
and three hours at a lower dose (A (240∙kg-1∙min-1), L (480 μg∙kg-1∙min-1), M (268 μg∙kg-1 ∙min-1)); controls received
normal saline. Hemodynamic, cardiac, pulmonary, metabolic and renal functions were evaluated.
Results: ALM lowered mean arterial pressure (Mean value during infusion period: ALM: 47 (95% confidence interval (CI):
44 to 50) mmHg versus control: 79 (95% CI: 75 to 85) mmHg, P <0.0001). After cessation of ALM, mean arterial pressure
immediately increased (end of study: ALM: 88 (95% CI: 81 to 96) mmHg versus control: 86 (95% CI: 79 to 94) mmHg,
P = 0.72). Whole body oxygen consumption was significantly reduced during ALM infusion (ALM: 205 (95% CI: 192 to
217) ml oxygen/min versus control: 231 (95% CI: 219 to 243) ml oxygen/min, P = 0.016). ALM treatment reduced
pulmonary injury evaluated by PaO2/FiO2 ratio (ALM: 388 (95% CI: 349 to 427) versus control: 260 (95% CI: 221 to 299),
P = 0.0005). ALM infusion led to an increase in heart rate while preserving preload recruitable stroke work. Creatinine
clearance was significantly lower during ALM infusion but reversed after cessation of infusion. ALM reduced tumor
necrosis factor-α peak levels (ALM 7121 (95% CI: 5069 to 10004) pg/ml versus control 11596 (95% CI: 9083 to 14805)
pg/ml, P = 0.02).
Conclusion: ALM infusion induces a reversible hypotensive and hypometabolic state, attenuates tumor necrosis factor-α
levels and improves cardiac and pulmonary function, and led to a transient drop in renal function that was
reversed after the treatment was stopped.* Correspondence: granfeldt@gmail.com
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Sepsis is associated with high mortality due to the devel-
opment of cardiovascular dysfunction, lung injury and
multiorgan failure [1,2]. The pathophysiology responsible
for the poor outcomes of sepsis is believed to be associated
with a simultaneous activation of pro-inflammatory and
anti-inflammatory pathways with different phases during
the course of sepsis dominated by either hyperinflamma-
tion or immunosuppression [3,4]. Initially the innate im-
mune system is activated in response to microorganisms,
leading to production of cytokines, reactive oxygen spe-
cies, and activation of leukocytes [5,6].
The combination of adenosine and lidocaine (AL) is
cardioprotective and is currently used as a cardioplegia
strategy in cardiac surgery [7,8]. AL has also been shown
to suppress neutrophil inflammatory functions to a greater
extent than either drug alone [9]. The cardioprotective
and anti-inflammatory properties of AL were expanded to
a porcine model of cardiac arrest and resuscitation [10]. In
addition, the combination of AL and Mg2+ (ALM) has
been reported to improve cardiovascular, hemodynamic
and pulmonary function and to reduce whole body oxygen
consumption (VO2) following severe hemorrhagic shock
and resuscitation [11-14]. Since cardiovascular dysfunction
and respiratory failure are the most frequent causes of
early death in septic patients [15], the effects of ALM may
also be protective in the setting of sepsis and systemic in-
flammation. In support of this, the rat model of cecal
ligation and puncture demonstrated that ALM prevented
coagulopathy and reduced pulmonary edema while tem-
porarily inducing reversible hypotension [16]. The current
study tested the hypothesis that intervention with ALM
will reduce tumor necrosis factor alpha (TNFα) peak levels
and improve cardiovascular and pulmonary function in re-
sponse to lipopolysaccharide in a porcine model.
Materials and methods
The study was approved by the National Committee on
Animal Research Ethics (2012-15-2934-00446; Glostrup,
Denmark) and was conducted in accordance with the
Principles of Laboratory Animal Care [17].
Animal preparation
Sixteen female crossbred Landrace/Yorkshire/Duroc pigs
(37 to 42 kg) were fasted overnight, but were allowed
free access to water. Anesthesia was induced with mid-
azolam (20 mg) and s-ketamin (250 mg) and maintained
with fentanyl (60 μg∙kg–1∙hour–1) and midazolam
(6 mg∙kg–1∙hour–1) as used in previous studies [13,18].
The animals were intubated and ventilated using pres-
sure control ventilation with the volume guaranteed (S/5
Avance; Datex Ohmeda, Madison, WI, USA) at a posi-
tive end-expiratory pressure of 5 cmH2O, a fraction of
inspired oxygen (FiO2) of 0.4, and a tidal volume of10 ml/kg. The ventilation rate was adjusted to maintain ar-
terial partial pressure of carbon dioxide between 41 and
45 mmHg. The body temperature was maintained around
38 to 38.5°C. All animals received a bolus of isotonic saline
10 ml/kg at baseline and a maintenance rate of 15 ml∙kg–1.
hour–1 during lipopolysaccharide infusion.
Surgical preparations and monitoring
Vascular sheaths were inserted into the carotid artery and
both external jugular veins. A pressure–volume catheter
(Transonic SciSense, London, Ontario, Canada) was inserted
into the left ventricle through the right carotid artery. A pul-
monary artery catheter (CCOmbo; Edwards Lifesciences, Ir-
vine, CA, USA) was inserted into the pulmonary artery
through the right external jugular vein to monitor cardiac
output and the core temperature. A PTS® sizing balloon
(NMT Medical, Boston MA, USA) was inserted in the left
external jugular vein and positioned into the vena cava to oc-
clude venous return during pressure–volume measurements.
A bladder catheter was placed for urine collection.
Systemic vascular resistance (dyn.s/cm5) was calculated as:
Systemic vascular resistance
¼ 80  MAP – central venous pressureð Þ
 cardiac output
where MAP is the mean arterial pressure. Pulmonary
vascular resistance (PVR, dyn.s/cm5) was calculated as:
PVR ¼ 80  MPAP – pulmonary capillary wedge pressureð Þ
 cardiac output
where MPAP is the mean pulmonary arterial pressure.
Experimental protocol
After instrumentation, each animal, was randomly
assigned to one of two groups: Group 1, control (n = 8);
Group 2, ALM (n = 8) (Figure 1). Following surgery and
instrumentation, randomization was performed by a la-
boratory technician drawing either control or ALM la-
bels from a paper bag. The primary investigators were
blinded to group assignments prior to infusion of ALM.
With initiation of ALM infusion there was a significant
drop in blood pressure, preventing blinding during the
remainder of the study. Analysis of blood samples and
data analysis were blinded to group assignment.
After randomization, endotoxemia was induced by in-
fusion of Escherichia coli lipopolysaccharide (0111:B4,
lot 011 m4008; Sigma-Aldrich, Broendby, Denmark) at a
rate of 1 μg∙kg–1∙hour–1 for 5 hours [18]. In both groups,
if MPAP increased to the level of MAP during the
first hour of ALM infusion where MPAP levels are at
the highest, an epinephrine bolus at a fixed dose of
0.002 mg was given to avoid circulatory collapse and
death as reported in previous studies [18,19]. Therapy
Figure 1 Schematic diagram of the study protocol. Pigs were randomly assigned in a blinded manner to one of two groups: Group 1,
control (n = 8); Group 2, adenosine, lidocaine and magnesium (ALM; n = 8). Animals were subjected to endotoxemia by infusion of Escherichia coli
lipopolysaccharide (LPS) at a rate of 1 μg∙kg–1.hour–1 for 5 hours. As LPS infusion was started, animals were loaded with a high-dose bolus
infusion of ALM (ALM(1)) followed by a continuous infusion of ALM (ALM(2)) for 1 hour, after which the formulation was decreased (ALM(3)) to
minimize hypotension.
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the difference between MPAP and MAP.
In the event of hypoxia (arterial partial pressure of
oxygen (PaO2) < 12 kPa), FiO2 was increased to 0.60 ini-
tially, and then if inadequate to 0.80.
Adenosine, lidocaine and magnesium treatment
Doses were determined by previous studies and pilot experi-
ments using a three-tier ALM strategy (Figure 1) [13,20,21].
As lipopolysaccharide infusion was started, animals were
loaded with a bolus infusion of ALM(1) (adenosine
(0.82 mg/kg), lidocaine (1.76 mg/kg) and magnesium sulfate
(0.92 mg/kg)) [10]; this was followed by a continuous infu-
sion of ALM(2) using adenosine (300 μg∙kg–1∙minute–1),
lidocaine (600 μg∙kg–1∙minute–1) and magnesium sulfate
(336 μg∙kg–1∙minute–1) for 1 hour, after which the formula-
tion was decreased to adenosine (240 μg∙kg–1∙minute–1),
lidocaine (480 μg∙kg–1∙minute–1) and magnesium sulfate
(268 μg∙kg–1∙minute–1) (ALM(3)) to minimize hypotension.
For continuous infusion, drugs were dissolved in 1 l normal
saline. In the control group, saline was used as a vehicle in-
fusion and the rate of infusion was turned off after 4 hours.
Observation was continued for a total of 5 hours.
Oxygen consumption
VO2 was calculated as the product of the arterial–mixed
venous oxygen content difference and cardiac output as
described previously [13]. Oxygen delivery is calculated as
the product of cardiac output and arterial oxygen content,
while the oxygen extraction ratio is calculated as the ratio
of arterial–venous difference and arterial oxygen content.
Analysis of blood and urine samples
Arterial blood gas analysis was performed every half hour
(ABL700; Radiometer, Broenshoej, Denmark). Blood plasmaand urine samples were collected hourly. Blood samples
were analyzed for creatinine, while urinary samples
were analyzed for creatinine, protein and N-acetyl-β-D-
glucosaminidase (NAGase) activity as described previously
[13]. Urinary levels of neutrophil gelatinase-associated lipo-
calin (NGAL) were determined using a commercially avail-
able enzyme-linked immunosorbent assay kit (BioPorto
Diagnostics A/S, Gentofte, Denmark) [22]. NGAL and
NAGase are both markers of tubular injury. Intra-assay
and inter-assay precisions were 2.71 and 6.27% respect-
ively. NAGase activity, protein and NGAL concentrations
in urine were divided by urinary creatinine concentrations
to correct for urine output.
Multiplex cytokine analysis
The concentration of the cytokines interleukin (IL)-6, IL-10,
and TNFα were determined using a commercially available
kit (Procarta® Porcine Cytokine Assay Kit; Panomics, San
Diego, CA, USA) [18]. Detection limits were, 4.39 pg/ml for
IL-6, 15.41 pg/ml for IL-10, and 14.45 pg/ml for TNFα.
Inter-assay variations were 4 to 13%, and intra-assay varia-
tions were 1 to 5%.
Leukocyte superoxide production
Blood samples were collected hourly and the number of
leukocytes was quantified using an Automated Hematology
Analyzer (KX-21 N; Sysmex Europe GmbH, Norderstedt,
Germany). Leukocyte superoxide anion (˙O2
–) generation
was quantified using lucigenin-enhanced chemilumines-
cence [9]. Each whole blood sample was divided into two
aliquots: whole blood alone; and whole blood + 0.2 mg/ml
opsonized zymosan. The leukocyte superoxide anion com-
ponent of the overall signal was demonstrated by adding
superoxide dismutase (3 mg/ml; Sigma Chemicals, St.
Louis, MO, USA). Lucigenin-enhanced chemiluminescence
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mat LP9507; Berthold Tech, Bad Wildbad, Germany) and
expressed as relative light units per 106 leukocytes. Data at
different time points are expressed as a percentage of base-
line chemiluminescence.
Pulmonary function
The alveolar–arterial oxygen difference was calculated
using the simplified alveolar gas equation:
PaO2 ¼ PATM– PH2Oð Þ  FiO2– PaCO2=R
where PATM is the atmospheric pressure, PH2O is the
saturated vapor pressure of water (49.7 mmHg), PaCO2
is the arterial partial pressure of carbon dioxide and R is
the respiratory quotient (0.8) [23]. To determine the
wet/dry lung tissue weight ratio, representative samples
of the right upper lung were weighed (wet weight) and
placed in an oven at 70°C until there was no further
weight loss (dry weight).
Cardiac function
Real-time pressure–volume loops were obtained using the
ADVantage™ system (Transonic SciSense), which uses an
admittance catheter to simultaneously measure left ven-
tricular pressure and admittance [24]. Data were continu-
ously recorded using a multichannel acquisition system
and Labchart software (ADInstruments, Oxford, UK). The
following pressure-derived data were recorded: end systolic
pressure, end diastolic pressure, time constant of isovolu-
mic relaxation (Tau), maximum rate of pressure develop-
ment over time (dP/dtmax), and maximum rate of pressure
decrease over time (dP/dtmin). Preload was reduced by in-
flating the vena caval sizing catheter during respiratory
apnea to obtain declining left ventricular pressure–volume
loops from which the load-independent indices of con-
tractility were calculated: preload recruitable stroke work
(PRSW), end systolic pressure–volume relationship (end
systolic elastance (Ees)), and end diastolic pressure–volume
relationship. Arterial–ventricular coupling was described
as the Arterial elastance (Ea) / Ees ratio. The optimal Ea/
Ees ratio is approximately 1 and a deviation from this indi-
cates a decrease in arterial–ventricular coupling efficiency
and cardiac performance.
Statistical analysis
For continuous variables, a repeated-measures analysis
of variance was used to analyze data for time-dependent
and between-group differences. It was determined a
priori to perform post-hoc pairwise comparisons at base-
line and at the end of the study; comparisons beyond
this were adjusted for multiple compassions (Sidak). The
repeated-measurements analysis of variance was a priori
divided into analysis of: the entire study period, and the4-hour ALM infusion period. The assumptions of the
models were investigated by inspecting scatter plots of
the residuals versus fitted values, and normal quantile
plots of the residuals and data were logarithmically
transformed when necessary. If data did not fulfill as-
sumptions for repeated-measures analysis of variance
despite logarithmical transformation, they were analyzed
using multivariate repeated-measurements analysis of
variance as reported previously [14,18].
All variables are presented on the original scale of
measurement as mean/median and 95% confidence in-
tervals (CIs). Two-tailed P < 0.05 was considered statisti-
cally significant.
Eight pigs being included in each group was based on
power calculations with data from six separate pilot
studies with respect to peak TNFα levels at 90 minutes
and a change in VO2 from before/after infusion was dis-
continued (TNFα: difference = 3,353 pg/ml; standard
deviation = 1,480; α = 0.05 and β =0.1, n = 5: VO2: differ-
ence = 79 ml oxygen/minute; standard deviation con-
trol = 54/ALM = 29; α = 0.05 and β = 0.1, n = 7). Power
calculations were performed with the primary endpoint
TNFα and the secondary endpoint VO2 since we wanted
to investigate whether the known anti-inflammatory and
metabolic lowering effects of ALM would translate into
an improvement in organ function. The analyses were per-
formed using Stata 12.1 (StataCorp LP, College Station,
TX, USA).
Results
Hemodynamic function
All reported baseline values are prior to the start of lipo-
polysaccharide and ALM infusion. ALM infusion resulted
in a significantly lower MAP during the 4-hour treatment
period (Figure 2A). At the end of ALM infusion, MAP im-
mediately returned to control group values. The lower
MAP during infusion of ALM was due to a lower systemic
vascular resistance (Table 1) despite a significantly higher
cardiac output (Figure 2B).
At the end of the study, both the heart rate and stroke
volume (SV) were significantly higher in the ALM group
versus the control group (Table 1). The use of intraven-
ous epinephrine was protocol driven to avoid circulatory
collapse and death if MPAP was equal to or greater than
MAP during the first 60 minutes [18]. A significantly
lower cumulative dose of epinephrine was administered
according to this protocol in the ALM group (ALM me-
dian, 0 (range 0 to 0.2) μg vs. control median, 0.6 (range
0 to 2.4) μg, P = 0.025).
Inflammation
Infusion of lipopolysaccharide caused a characteristic
increase in plasma cytokines (Table 2, Figure 3A). Peak
TNFα levels after 90 minutes of lipopolysaccharide infusion
Figure 2 Hemodynamic and metabolic data. Treatment with adenosine, lidocaine and magnesium (ALM) induced reversible hypotension,
increased cardiac output and decreased oxygen consumption and oxygen extraction during infusion of ALM. (A) Mean arterial pressure. (B) Cardiac
output. (C) Whole body oxygen consumption. (D) Whole body oxygen extraction. *Significant difference at the end of the study. #Significantly
different change over time between groups. †Significantly different mean/median level during infusion of ALM. ¥Significant difference before/after
cessation of ALM infusion. Data presented as median (95% confidence interval), except for oxygen consumption which is presented as mean
(95% confidence interval). LPS, lipopolysaccharide.
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ratio, 1.63 (95% CI: 1.11 to 2.38); P = 0.02). No significant
difference existed between groups with regards to IL-6 or
IL-10. The total blood leukocyte count decreased over time,
with no group differences (Figure 3B). In vitro superoxide
anion production was significantly lower in the ALM group
when compared with the control group (Figure 3C,D).
Metabolic function
As a consequence of the higher cardiac output, global oxy-
gen delivery was significantly greater in the ALM group
(Table 3). However, the average whole body VO2 during
the infusion period was significantly lower than for con-
trols (ALM, 205 (95% CI: 192 to 217) ml oxygen/minute
vs. control, 231 (95% CI: 219 to 243) ml oxygen/minute,
P = 0.016; Figure 2C), while it immediately returned to
control group values after cessation of ALM treatment.
The oxygen extraction ratio was unchanged in the
ALM group, supporting a favorable oxygen supply/de-
mand status (Figure 2D). In direct contrast, the ratio in-
creased over time in the control group, consistent with
inadequate delivery of oxygen.Lactate was significantly lower in the ALM group at
the end of the study (Table 4).
Pulmonary function
Infusion of lipopolysaccharide caused a characteristic in-
crease in MPAP with a peak at 30 minutes; this increase
was avoided in the ALM group (Figure 4A). ALM main-
tained a significantly lower MPAP during the entire
study. There was an initial peak in PVR at 30 minutes in
the control group but this was not seen in the ALM
group (Table 1). PVR continued to be lower during the
entire study in the ALM group.
A positive end-expiratory pressure of 5 cmH2O and a
tidal volume of 10 ml/kg were delivered to all pigs
throughout the study. Peak respiratory pressures and re-
spiratory rates increased over time in both groups with
no difference between groups (Table 3).
The alveolar–arterial oxygen difference was main-
tained in the ALM group while it increased over time in
the control group with a significant difference at the end
of the study (Figure 4B). Similarly, the PaO2/FiO2 ratio
was maintained in the ALM group, while it decreased
Table 1 Systemic hemodynamic variables
Baseline 30 minutes 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 210 minutes 240 minutes 270 minutes 300 minutes
Heart rate
(min–1)
Control 69
(62 to 76)
83
(76 to 90)
84
(77 to 91)
74
(67 to 81)
73
(66 to 80)
77
(69 to 84)
75
(68 to 82)
70
(63 to 77)
69
(62 to 76)
70
(63 to 77)
71
(64 to 78)
ALMa 69
(62 to 76)
70
(63 to 77)
72
(65 to 79)
76
(69 to 83)
81
(74 to 88)
84
(77 to 91)
84
(77 to 91)
81
(74 to 88)
80
(73 to 87)
84 (76 to 91) 84b
(77 to 91)
Systemic
vascular
resistance
(dyn.s/cm5)
Control 1,526
(1,328 to 1,753)
1,242
(1,081 to 1,427)
1,141
(993 to 1,310)
1,177
(1,024 to 1,352)
1,210
(1,054 to 1,390)
1,501
(1,306 to 1,724)
1,768
(1,539 to 2,031)
2,245
(1,954 to 2,579)
2,327
(2,025 to 2,673)
2,357
(2,0151 to 2,707)
2,145
(1,867 to 2,464)
ALMa 1,500
(1,306 to 1,723)
607
(528 to 697)
63
(553 to 730)
652
(568 to 749)
644
(561 to 740)
689
(600 to 792)
710
(618 to 816)
742
(646 to 852)
816
(710 to 937)
1,630c
(1,418 to 1,872)
1,472b
(1,282 to 1,691)
Pulmonary
vascular
resistance
(dyn. s/cm5)
Control 131
(109 to 157)
688
(574 to 826)
461
(384 to 553)
331
(276 to 397)
318
(265 to 382)
481
(401 to 577)
585
(488 to 702)
656
(547 to 787)
665
(554 to 797)
640
(533 to 767)
567
(473 to 681)
ALMa 154
(129 to 185)
173d
(144 to 208)
165
(138 to 198)
190
(159 to 228)
246
(205 to 295)
314
(262 to 377)
324
(270 to 388)
333
(277 to 399)
330
(276 to 396)
351
(293 to 421)
300b
(250 to 360)
Stroke
volume (ml)
Control 63
(58 to 68)
46
(41 to 50)
54
(49 to 59)
67
(62 to 72)
67
(62 to 72)
54
(49 to 59)
48
(43 to 53)
43
(38 to 48)
40
(35 to 45)
39
(34 to 44)
42
(37 to 47)
ALMa 61
(56 to 66)
65
(61 to 70)
60
(55 to 65)
65
(60 to 69)
63
(58 to 68)
59
(55 to 64)
58
(54 to 63)
57
(52 to 62)
52
(48 to 57)
52
(47 to 57)
53b
(48 to 58)
Data presented as median (95% confidence interval), except for heart rate and stroke volume which are presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium. aSignificantly different
change over time between groups. bSignificant difference at the end of the study. cSignificant difference before/after cessation ALM infusion. dSignificant difference between groups (Sidak).
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Table 2 Plasma cytokines and renal function
Baseline 30 minutes 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 210 minutes 240 minutes 300 minutes
Interleukin-6
(pg/ml)
Control 6 (4 to 10) 5 (3 to 8) 4 (2 to 6) 32 (19 to 53) 107 (65 to 178) 168 (102 to 279) 221 (133 to 366) 174 (105 to 289) 83 (50 to 138)
ALM 4 (3 to 7) 4 (3 to 7) 6 (4 to 10) 45 (27 to 75) 177 (107 to 293) 272 (164 to 451) 339 (204 to 561) 266 (161 to 441) 90 (54 to 149)
Interleukin-10
(pg/ml)
Control 5 (3 to 8) 10 (6 to 17) 327 (201 to 532) 391 (240 to 636) 215 (132 to 350) 213 (131 to 347) 392 (241 to 638) 419 (257 to 681) 315 (194 to 512)
ALM 6 (4 to 11) 14 (8 to 22) 303 (186 to 492) 463 (285 to 754) 341 (209 to 554) 297 (182 to 483) 347 (213 to 564) 354 (218 to 576) 383 (235 to 623)
Urinary protein/
creatinine
ratio (μg/μmol)
Control 7.5 (5.5 to 10.3) 7.6 (5.5 to 10.4) 9.4 (6.8 to 12.9) 10.1 (7.4 to 13.9) 10.2 (7.5 to 14.1) 11.1 (8.1 to 15.2)
ALMa 9.1 (6.6 to 12.5) 8.4 (6.1 to 11.5) 14.1 (10.1 to 19.3) 24.3 (17.7 to 33.4) 19.5 (14.2 to 26.7) 14.7 (10.7 to 20.2)
Urinary NAGase/
creatinine
ratio (U/mmol)
Control 2.2 (1.5 to 3.3) 2.0 (1.3 to 3.0) 2.2 (1.5 to 3.3) 1.8 (1.2 to 2.8) 1.8 (1.2 to 2.8) 2.2 (1.4 to 3.3)
ALMb 2.1 (1.4 to 3.2) 2.1 (1.4 to 3.2) 3.0 (2.0 to 4.5) 6.3 (4.2 to 9.5) 6.5 (4.3 to 9.7) 3.0c (2.0 to 4.5)
Data presented as median (95% confidence interval). ALM, adenosine, lidocaine and magnesium; NAGase, N-acetyl-β-D-glucosaminidase. aSignificantly different mean/median level. bSignificantly different change over
time between groups. cSignificant difference before/after cessation ALM infusion.
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Figure 3 Tumor necrosis factor alpha and leukocyte data. (A) Peak tumor necrosis factor alpha (TNFα) levels were significantly lower in the
treatment group. (B) Total blood leukocyte count decreased over time with no group difference. (C) A dose–response relationship with regards
to superoxide anion production was observed and the leukocyte superoxide anion (˙O2
–) component of the overall signal was demonstrated by
adding superoxide dismutase. (D) Superoxide anion production, stimulated by low-dose opsonized zymosan 0.02 mg/ml, was significantly
attenuated in the treatment group. *Significant difference between groups. #Significantly different change over time between groups. Data
presented as median (95% confidence interval). ALM, adenosine, lidocaine and magnesium; LPS, lipopolysaccharide; OpZ, opsonized zymosan;
SOD, superoxide dismutase.
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cantly higher level in the ALM group (Figure 4C). Treat-
ment with ALM significantly reduced the mean
pulmonary wet/dry ratio when compared with the con-
trol group (Figure 4D).
Cardiac function
The slope of Ees did not change significantly over time
in either group (Figure 5A,B, Table 5). However, a right-
ward shift of the volume axis intercept was observed in
the control group, consistent with a decrease in con-
tractility; this shift was prevented in the ALM group
(Figure 5A,B, Table 5). The slope of the PRSW, an index
of overall cardiac performance, decreased in the control
group but was preserved in the ALM group (Figure 5C,
D, Table 5). In both groups there was a rightward shift
in the intercept of PRSW with no significant group dif-
ference at the end of the study. Another index of cardiac
contractility, dP/dtmax was significantly higher in the
ALM group at the end of the study when compared
with the control group, at equal pressures (Figure 6A,B).
The end-diastolic pressure–volume relationship did notchange significantly over time and there was no group
difference (data not shown). However, diastolic function
evaluated by dP/dtmin and Tau was significantly im-
proved in the ALM group (Figure 6C, Table 5). Arterial–
ventricular coupling (Ea/Ees) increased progressively in
the controls during the course of the experiment, con-
sistent with mismatched coupling. This was not ob-
served in the ALM group during ALM infusion, whereas
the Ea/Ees ratio increased to control group levels after
infusion was discontinued (Figure 6D).
Renal function
Urine output decreased significantly during infusion of
ALM (Figure 7A) but the production increased rapidly
after ALM was discontinued, resulting in a significantly
higher urine output in the ALM group when compared
with controls at the end of the study. Despite these tem-
poral differences, there was no significant difference in
total urine production during the entire study (ALM,
487 (95% CI: 236 to 738) ml vs. control, 544 (95% CI:
300 to 788) ml). Plasma creatinine levels increased
steadily in the ALM group during infusion (Figure 7B).
Table 3 Oxygen consumption variables
Baseline 30 minutes 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 210 minutes 240 minutes 270 minutes 300 minutes
Oxygen delivery
(ml O2/minute)
Control 556
(492 to 629)
436
(386 to 493)
607
(537 to 686)
692
(612 to 782)
696
(616 to 787)
592
(523 to 669)
533
(472 to 603)
438
(388 to 495)
423
(374 to 478)
410
(363 to 463)
441
(390 to 498)
ALMa 527
(466 to 595)
569
(504 to 644)
571
(505 to 645)
686
(607 to 776)
742
(656 to 838)
740
(655 to 837)
710
(628 to 803)
670
(592 to 757)
602
(533 to 681)
619
(548 to 700)
648b
(574 to 733)
Arterial–venous
difference
(ml O2/l blood)
Control 50
(46 to 55)
69
(63 to 75)
48
(44 to 52)
48
(44 to 52)
52
(47 to 57)
57
(52 to 63)
68
(62 to 74)
73
(67 to 80)
78
(71 to 85)
78
(72 to 86)
74
(68 to 81)
ALMa 48
(44 to 53)
51
(47 to 56)
44 (40 to 48) 42
(39 to 46)
41
(38 to 45)
40
(37 to 44)
42
(38 to 45)
46
(42 to 51)
46
(42 to 50)
51
(46 to 56)
50b
(45 to 54)
Respiratory rate
(min–1)
Control 12
(11 to 13)
12
(11 to 12)
13
(12 to 13)
13
(12 to 14)
13
(13 to 14)
13
(13 to 14)
14
(13 to 14)
14
(13 to 15)
14
(13 to 15)
14
(14 to 15)
14
(14 to 15)
ALM 13
(13 to 14)
13
(12 to 13)
13
(12 to 13)
13
(12 to 14)
13
(12 to 14)
14
(13 to 14)
13
(13 to 14)
14
(13 to 14)
14
(13 to 14)
14
(13 to 15)
14
(14 to 15)
Airway peak
pressure
(cmH2O)
Control 19
(18 to 20)
21
(20 to 22)
21
(20 to 22)
21
(20 to 22)
22
(21 to 23)
23
(22 to 24)
24
(23 to 25)
24
(23 to 25)
25
(24 to 26)
25
(24 to 26)
25
(24 to 26)
ALM 19
(18 to 20)
21
(20 to 22)
21
(20 to 22)
22
(21 to 23)
22
(21 to 23)
23
(22 to 24)
24
(22 to 25)
24
(23 to 25)
24
(23 to 25)
24
(23 to 25)
24
(23 to 25)
Data presented as median (95% confidence interval), except for temperature which is presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium. aSignificant different change over time
between groups. bSignificant difference at the end of the study.
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Table 4 Systemic arterial gas and metabolic variables
Baseline 30 minutes 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 210 minutes 240 minutes 270 minutes 300 minutes
Arterial pH
Control 7.48
(7.47 to 7.49)
7.48
(7.47 to 7.50)
7.44
(7.43 to 7.46)
7.44
(7.42 to 7.45)
7.44
(7.42 to 7.45)
7.42
(7.40 to 7.43)
7.41
(7.40 to 7.43)
7.41
(7.39 to 7.42)
7.41
(7.40 to 7.43)
7.41
(7.40 to 7.42)
7.41
(7.39 to 7.42)
ALM 7.48
(7.47 to 7.50)
7.48
(7.46 to 7.49)
7.45
(7.44 to 7.46)
7.44
(7.42 to 7.45)
7.41
(7.40 to 7.43)
7.41
(7.40 to 7.43)
7.40
(7.39 to 7.42)
7.40
(7.39 to 7.42)
7.40
(7.38 to 7.42)
7.40
(7.38 to 7.41)
7.40
(7.39 to 7.41)
PaO2
(mmHg)
Control 182
(161 to 205)
118
(105 to 135)
154
(136 to 173)
157
(139 to 177)
144
(127 to 162)
117
(103 to 132)
111
(98 to 125)
110
(98 to 124)
127
(112 to 143)
126
(111 to 142)
115
(102 to 130)
ALMa 184
(163 to 207)
173
(154 to 196)
174
(154 to 197)
169
(150 to 191)
168
(148 to 189)
170
(150 to 191)
167
(148 to 188)
163
(144 to 184)
150
(133 to 169)
151
(134 to 171)
147b
(130 to 166)
PaCO2
(mmHg)
Control 43
(42 to 44)
41
(40 to 42)
44
(42 to 45)
44
(42 to 45)
44
(43 to 45)
44
(43 to 46)
45
(44 to 46)
45
(44 to 46)
44
(43 to 45)
43
(42 to 44)
44
(43 to 45)
ALM 43
(41 to 44)
41
(40 to 42)
42
(41 to 44)
42
(41 to 44)
44
(43 to 35)
44
(42 to 45)
44
(43 to 45)
43
(42 to 44)
44
(42 to 45)
45
(44 to 46)
45
(44 to 46)
ETCO2 (mmHg)
Control 43
(42 to 45)
42
(41 to 43)
45
(44 to 47)
45
(44 to 46)
44
(43 to 45)
43
(42 to 45)
42
(40 to 43)
41
(39 to 42)
40 v(39 to 41) 40
(39 to 41)
40
(39 to 41)
ALMc 45
(44 to 46)
42
(41 to 44)
45
(44 to 46)
45
(43 to 46)
45
(44 to 47)
44
(43 to 46)
45
(44 to 46)
44
(42 to 45)
44
(43 to 45)
44
(43 to 45)
44b
(42 to 45)
HCO3
–
(mmol/l)
Control 31.4
(30.6 to 32.2)
30.5
(29.7 to 31.3)
29.1
(28.3 to 29.9)
28.7
(27.9 to 29.4)
28.7
(27.9 to 29.4)
27.8
(27.1 to 28.6)
27.6
(26.8 to 28.4)
27.1
(26.3 to 27.9)
26.9
(26.1 to 27.7)
26.6
(25.8 to 27.4)
26.8
(26.0 to 27.6)
ALM 31.4
(30.7 to 32.2)
30.3
(29.5 to 31.0)
29.0
(28.2 to 29.8)
28.1
(27.3 to 28.8)
27.4
(26.6 to 28.1)
27.0
(26.2 to 27.7)
26.6
(25.8 to 27.4)
26.5
(25.7 to 27.3)
26.1
(25.3 to 26.9)
26.4
(25.6 to 27.1)
26.6
(25.8 to 27.4)
Lactate
(mmol/l)
Control 0.8
(0.6 to 0.9)
0.8
(0.6 to 1.0)
1.1
(0.9 to 1.2)
1.1
(0.9 to 1.2)
1.2
(1.0 to 1.3)
1.2
(1.1 to 1.4)
1.3
(1.1 to 1.4)
1.3
(1.2 to 1.5)
1.3
(1.2 to 1.5)
1.2
(1.1 to 1.4)
1.1
(0.9 to 1.2)
ALMc 0.7
(0.6 to 0.9)
1.0
(0.8 to 1.1)
1.2
(1.0 to 1.3)
1.2
(1.0 to 1.4)
1.2
(1.0 to 1.4)
1.2
(1.0 to 1.3)
1.2
(1.0 to 1.3)
1.1
(1.0 to 1.3)
1.1
(0.9 to 1.3)
1.0
(0.8 to 1.1)
0.8b
(0.7 to 1.0)
Data presented as median (95% confidence interval), except for pH, lactate, and ETCO2 which are presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium; ETCO2, end-tidal carbon
dioxide; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen.
aSignificantly different mean/median level between groups. bSignificant difference at the end of the study.
cSignificantly different change over time between groups.
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Figure 4 Pulmonary function. Infusion of adenosine, lidocaine and magnesium (ALM) improved pulmonary function, indicated by a lower
mean pulmonary arterial pressure, a lower alveolar–arterial oxygen difference, a lower wet/dry ratio and a higher PaO2/FiO2 ratio. (A) Mean
pulmonary arterial pressure. (B) Alveolar–arterial oxygen difference. (C) PaO2/FiO2 ratio. (D) Pulmonary wet/dry ratio. *Significant difference at the
end of the study. #Significantly different change over time between groups. ¥Significant difference before/after cessation ALM infusion. Mean
pulmonary arterial pressure and PAO2–PaO2 difference are presented as median (95% confidence interval), while the PaO2/FiO2 ratio is presented
as mean (95% confidence interval). Pulmonary wet/dry ratio presented as mean and individual values. FiO2, inspired fraction of oxygen; LPS,
lipopolysaccharide; PaO2, arterial partial pressure of oxygen; PAO2, alveolar partial pressure of oxygen.
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an immediate decrease in plasma creatinine. Creatinine
levels remained 33% higher at the end of the study in
the ALM group.
The higher plasma creatinine level during ALM infu-
sion was due in part to decreased creatinine clearance.
However, creatinine clearance was significantly higher in
the ALM group when compared with controls after infu-
sion was discontinued (Figure 7C). Both the urinary pro-
tein/creatinine ratio and NAGase/creatinine ratio
increased in the ALM group during ALM infusion but
returned to values comparable with the control group
after infusion was turned off (Table 2). There was a sig-
nificantly different development over time between
groups with regards to the urinary NGAL/creatinine ra-
tio; however, no significant group difference existed at
the end of the study (Figure 7D). Overall markers of
renal dysfunction increased in the ALM group during
infusion of ALM, but returned to control group levels
after the infusion, with the exception of higher plasma
creatinine levels and an increase in creatinine clearance
in the ALM group compared with controls.Discussion
In the present study, we showed in an endotoxemic por-
cine model that treatment with ALM improved cardiac
function, increased the PaO2/FiO2 ratio with lower lung
wet/dry ratios, and reduced inflammation indicated by
lower TNFα levels and superoxide anion production.
ALM therapy induced a transient hypotensive state and
higher heart rates during infusion, with significantly
higher oxygen delivery and lower whole body VO2 than
controls. The hemodynamic status normalized immedi-
ately after discontinuation of therapy. In addition, ALM
led to a transient drop in renal function during infusion
that was reversed after the treatment was stopped.
Adenosine, lidocaine and magnesium treatment
The treatment regime and dosing of ALM was deter-
mined from our published rat and porcine hemorrhage
studies [10,13,20], and from pilot studies in the lipopoly-
saccharide porcine model. An intravenous bolus of ALM
was administered at the start of lipopolysaccharide infu-
sion as a loading dose to increase concentrations in the
vascular compartment, followed by constant infusion.
Figure 5 Pressure–volume data. Linear plots of the end systolic pressure–volume relationship (ESVPR; end systolic elastance) and the preload
recruitable stroke work (PRSW) in the control group and the adenosine, lidocaine and magnesium (ALM) group at baseline and at the end of the
study. (A) Linear plot of ESVPR in the control group at baseline and at the end of the study. (B) Linear plot of ESPVR in the adenosine, lidocaine
and magnesium (ALM) group at baseline and at the end of the study. (C) Linear plot of PRSW in the control group at baseline and at the end of
the study. (D) Linear plot of PRSW in the ALM group at baseline and at the end of the study. Both the end-systolic pressure–volume relationship
and the preload recruitable stroke work are defined by a slope and a volume axis intercept taken from data presented in Table 4 and are presented
since changes in the slope and intercept can be viewed simultaneously. *Significant difference at the end of the study. LV, left ventricular.
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to minimize further hypotension based on our pilot
studies. Magnesium sulfate was added to AL (making
ALM) based on its ability to improve hemodynamics
and correct coagulopathy in a rat model of hemorrhagic
shock [12,25].
This current study tested the combination ALM and
not its individual components because in previous studies
we have shown that it is the unique combination of ALM
that exerts synergistic effects related to hemodynamic sta-
bility [12,25], myocardial salvage [20] and neutrophil acti-
vation [9], which were not conferred by the individual
drugs alone.
Hemodynamic response to ALM treatment
The current study was a proof-of-concept study with intri-
guing findings as organ function was improved during a
transient pharmacologically induced hypotensive state. In
the present study, ALM induced a reversible hypotensive
state with MAP of 47 mmHg. We further showed that this
hypotensive state was stable and associated with improve-
ments in cardiac and pulmonary function, increased oxy-
gen delivery, and normal lactate levels. Interestingly, usingthe same anesthesia and same size pigs, we have previ-
ously shown that a single bolus of ALM during resuscita-
tion following hemorrhagic shock, despite the vasodilatory
properties of each of its components [26-28], increased
MAP from a shock state of 37 mmHg to ~48 mmHg with
significantly lower blood lactate levels than controls [14].
Similarly, in the present study, despite MAP of 47 mmHg
in normovolemic ALM pigs, cardiac function was im-
proved and lactate levels were significantly lower than in
controls at the end of the study. We conclude that the
ALM-induced hypotensive state during lipopolysaccharide
infusion had no signs of severe whole body ischemia with
a balanced oxygen supply/demand.
Although the Surviving Sepsis Campaign guidelines
endorse maintaining MAP greater than 65 mmHg [29],
organ protection was observed despite the temporary
pharmacologically induced hypotension during ALM infu-
sion. It is important to distinguish between pathological
hypotension and pharmacologically induced hypotension.
Pathologically induced hypotension as a consequence of
sepsis and systemic inflammation results in reduced tissue
perfusion, increased lactate levels caused by adrenergic ac-
tivation of glycolysis, a decrease in utilization and hypoxia,
Table 5 Cardiac function variables
Baseline 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 210 minutes 240 minutes 270 minutes 300 minutes
EEs slope
(mmHg/ml)
Control 1.01 (0.82 to 1.24) 0.88 (0.71 to 1.08) 0.69 (0.56 to 0.85) 0.64 (0.52 to 0.79) 0.73 (0.59 to 0.90) 0.72 (0.58 to 0.88) 0.81 (0.66 to 0.99) 0.89 (0.72 to 1.09) 0.94 (0.77 to 1.16) 0.88 (0.71 to 1.08)
ALM 0.86 (0.7 to 1.06) 1.05 (0.82 to 1.34) 0.79 (0.64 to 0.97) 0.79 (0.65 to 0.98) 0.81 (0.66 to 1.00) 0.74 (0.60 to 0.91) 0.78 (0.63 to 0.95) 0.73 (0.60 to 0.90) 0.82 (0.67 to 1.01) 0.89 (0.72 to 1.10)
EEs V0 (ml)
Control –38 (–56 to –20) –40 (–58 to –22) –64 (–82 to –45) –63 (–81 to –45) –51 (–69 to –32) –47 (–65 to –28) –25 (–43 to –7) –10 (–28 to 9) –5 (–23 to 13) 0 (–18 to 18)
ALMa –48 (–66 to –30) –7 (–29 to 14) –25 (–43 to –7) –26 (–45 to –8) –29 (–47 to –11) –31 (–49 to –13) –23 (–41 to –5) –30 (–48 to –12) –39 (–57 to –21) –33b (–51 to –14)
PRSW slope
(mmHg.ml/ml)
Control 7
0 (58 to 84)
50 (41 to 60) 51 (42 to 61) 42 (35 to 51) 43 (36 to 52) 38 (32 to 46) 40 (33 to 48) 33 (27 to 39) 34 (28 to 41) 36 (30 to 43)
ALMa 70 (59 to 85) 72 (59 to 88) 64 (54 to 77) 61 (51 to 74) 57 (48 to 69) 56 (46 to 67) 48 (40 to 57) 58 (48 to 70) 66 (54 to 79) 61b (51 to 74)
PRSW V0 (ml)
Control 33 (22 to 44) 24 (13 to 34) 26 (15 to 37) 10 (–1 to 21) 23 (12 to 34) 25 (14 to 35) 45 (34 to 56) 41 (30 to 52) 51 (40 to 61) 51 (40 to 61)
ALMa 27 (16 to 38) 43 (31 to 56) 46 (35 to 57) 43 (32 to 53) 38 (27 to 48) 41 (30 to 52) 43 (32 to 54) 52 (41 to 62) 37c (26 to 48) 45 (34 to 56)
Tau
(milliseconds)
Control 32 (29 to 35) 30 (28 to 33) 35 (32 to 38) 35 (32 to 38) 37 (34 to 40) 38 (35 to 42) 41 (38 to 45) 44 (40 to 48) 44 (41 to 48) 44 (40 to 48)
ALMa 31 (28 to 34) 33 (30 to 36) 31 (28 to 34) 30 (28 to 33) 32 (29 to 35) 33 (30 to 36) 35 (32 to 38) 36 (33 to 39) 37 (34 to 40) 36b (33 to 39)
Aortic elastance
(mmHg/ml)
Control 1.3 (1.1 to 1.5) 1.3 (1.1 to 1.5) 1.2 (1.0 to 1.3) 1.2 (1.1 to 1.4) 1.5 (1.3 to 1.7) 1.6 (1.4 to 1.9) 1.9 (1.7 to 2.2) 2.1 (1.8 to 2.4) 2.2 (1.9 to 2.5) 1.9 (1.7 to 2.2)
ALMa 1.2 (1.1 to 1.4) 0.9 (0.8 to 1.0) 0.8 (0.7 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.1) 1.1 (0.9 to 1.2) 1.1 (0.9 to 1.2) 1.6c (1.4 to 1.9) 1.5b (1.3 to 1.8)
Data presented as median (95% confidence interval), except for Ees V0 and PRSW V0 which are presented as mean (95% confidence interval). ALM, adenosine, lidocaine and magnesium; Ees, end systolic elastance;
PRSW, preload recruitable stroke work; V0, volume axis intercept.
aSignificantly different change over time between groups. bSignificant difference at the end of the study. cSignificant difference before/after cessation
ALM infusion.
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Figure 6 Cardiac function. During infusion of adenosine, lidocaine and magnesium (ALM), the end systolic pressure was significantly lower resulting
in an improved arterial–ventricular coupling. Furthermore, systolic and diastolic function evaluated by dP/dtmax and dP/dtmin respectively was improved
at the end of the study in the ALM group. (A) End systolic pressure. (B) Maximum rate of pressure development over time (dP/dtmax). (C) Maximum
rate of pressure decrease over time (dP/dtmin). (D) Ventricular–arterial coupling. *Significant difference at the end of the study. #Significant different
change over time between groups. †Significant different mean/median level during infusion of ALM. ¥Significant difference before/after cessation of
ALM infusion. Data presented as median (95% confidence interval). Ea, arterial elastance; Ees, end systolic elastance (end systolic pressure–volume
relationship); LPS, lipopolysaccharide.
Granfeldt et al. Critical Care  (2014) 18:682 Page 14 of 19which if not corrected leads to organ dysfunction and in-
creases mortality [30-32]. In contrast, pharmacologically
induced hypotension as observed in the current study was
associated with improved oxygen delivery and organ func-
tion. The concerns over inadequate tissue perfusion and en-
ergy supply/demand mismatch during hypotension in the
septic patient may not be the same when hypotension is in-
duced pharmacologically by drugs that maintain adequate
organ and whole body oxygen supply/demand status and
avoid anaerobic metabolism, and exert anti-inflammatory
effects. Future studies are therefore warranted in which the
hypotensive effects of the treatment with ALM are tested in
models more closely representing the septic patient with
hemodynamic instability.
Furthermore, whether the decrease in MAP is a poten-
tial protective mechanism or a potential side effect of the
treatment needs to be further elucidated. It would be in-
teresting to examine different doses of ALM on the effect
of MAP with and without the infusion of vasopressors.
The heart rate was significantly higher in the ALM
group compared with the control group at the end of
the study, which may be detrimental because studieshave demonstrated that heart rate >95 min–1 was associ-
ated with a higher mortality, leading to the use of beta
blockers to improve outcome [33-35]. Higher heart rates
in the present study are interesting because adenosine,
lidocaine and Mg2+ individually possess negative chrono-
tropic effects, as we have recently reported in the por-
cine model of hemorrhagic shock [14,36]. In our study,
it appears that in the ALM group the positive chronotro-
pic response caused by hypotension to maintain cardiac
output and oxygen delivery overruled the known nega-
tive chronotropic effects of the individual drugs.
Cardiac function
In the current study, lipopolysaccharide infusion impaired
both systolic and diastolic function, and arterial–ventricular
coupling. Systolic dysfunction was evident in controls by a
rightward shift of the Ees and a decrease in dP/dtmax and
the slope of the PRSW. Diastolic dysfunction was evident by
an increase in Tau and dP/dtmin. The present study did not
investigate the cellular mechanisms of lipopolysaccharide-
induced dysfunction, but these may include lipid peroxidation,
abnormal calcium handling, production of inflammatory
Figure 7 Renal function. A temporary impairment of renal function was observed during infusion of adenosine, lidocaine and magnesium
(ALM), demonstrated by a decrease in urine output and creatinine clearance and an increase in plasma creatinine levels; however, this
reversed after infusion was turned off. (A) Urine output during the study, measured hourly. (B) Plasma creatinine levels. (C) Creatinine clearance.
(D) Urinary neutrophil gelatinase-associated lipocalin (NGAL)/creatinine ratio. *Significant difference at the end of the study. #Significantly different
change over time between groups. †Significantly different development over time during infusion of ALM. ¥Significant difference before/after
cessation ALM infusion. Data presented as median (95% confidence interval), except for creatinine clearance that is presented as mean (95%
confidence interval). LPS, lipopolysaccharide.
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ALM resulted in a significant and clinically relevant improve-
ment in all measured cardiac functional parameters after
5 hours of observation. The reduction in neutrophil activation
and TNFα release with ALMmay be a mechanism underlying
cardioprotection as these mediators are known to depress
myocardial function [38,39].
In our study, lipopolysaccharide infusion increased the
Ea/Ees ratio in the control group over time as reported
in other studies [40], which indicates a decrease in coup-
ling efficiency and cardiac performance. This increase in
the Ea/Ees ratio was prevented in the ALM group during
the infusion period only. The decrease in SV and appar-
ent loss in arterial–ventricular coupling efficiency ob-
served in controls may be linked to a higher MPAP, and
possibly right heart dysfunction contributing to a lower
SV. Since Ees was unchanged in the ALM group, the
lower Ea/Ees ratio in the ALM group was due largely to
a significantly lower Ea (end systolic pressure/SV) rela-
tive to controls [41]. Hence, ALM optimizes arterial–
ventricular coupling by reducing MAP and unloading
the heart and by lowering MPAP and increasing SV.Pulmonary function
Intravenous administration of lipopolysaccharide is a
widely used and relevant model of acute lung injury
[23,42]. In the present study, acute lung injury was evi-
dent in controls by a decrease in the PaO2/FiO2 ratio,
an increase in the alveolar–arterial oxygen difference, a
higher MPAP, and an increase in the wet/dry ratio.
Treatment with ALM improved the pulmonary status,
manifested by a significantly higher PaO2/FiO2 ratio, a
lower alveolar–arterial oxygen difference, lower MPAP,
and a lower wet/dry ratio. At the end of the study, the
PaO2/FiO2 ratio was 260 (95% CI: 221 to 299) in the
control group and 388 (95% CI: 349 to 427) in the ALM
group with a difference of 129 (95% CI: 73 to 184), which
we regard as a clinically relevant difference. Following
lipopolysaccharide infusion, pulmonary dysfunction and
the increase in wet/dry ratio are most probably related to
a combination of elevated microvascular pressure and in-
creased vascular permeability [43].
The improvement in the wet/dry ratio and oxygen-
ation with ALM treatment may relate to both a reduc-
tion in PVR and a reduction in vascular permeability.
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cine model that infusion of adenosine reduced extravas-
cular lung water content without a reduction in MPAP
[44], suggesting that the lower wet/dry ratio may in
part be related to preserved endothelial integrity. Fur-
thermore, Feng and colleagues have demonstrated that
lidocaine alone attenuates acute lung injury through in-
hibition of nuclear factor-κΒ activation [45]. In our
study, this is consistent with the observed significant de-
crease in TNFα production and leukocyte superoxide
anion production, which are known mediators of endo-
thelial dysfunction. However, treatment with ALM also
caused a significant reduction in PVR, supporting our
contention that the improvement in pulmonary function
is related to both improved vascular permeability and a
reduction in PVR.
Acute kidney injury
Renal dysfunction is a common finding in septic pa-
tients, and previous animal studies have demonstrated
that targeting a lower MAP resulted in a higher incidence
of acute kidney injury [46], which is why we meticulously
evaluated renal function using several parameters as add-
itional impairment mediated by pharmacological induced
hypotension may be of concern. Adenosine, for example,
is believed to be involved in regulation of tubuloglomeru-
lar feedback, and infusion in humans increases renal blood
flow and lowers the glomerular filtration rate [47,48].
The adenosine-mediated decrease in the glomerular filtra-
tion rate is mediated by A1 receptor activation and
pre-glomerular vasoconstriction, whereas A2 receptor ac-
tivation medicates post-glomerular arteriolar vasodilation
reducing filtration pressure and cortical blood flow but
preserving renal juxtamedullary blood flow [47-49]. In the
present study, urine output and creatinine clearance de-
creased while plasma creatinine increased as a conse-
quence of a reduced filtration pressure. During the ALM
infusion, markers of tubular injury (NGAL and NAGase)
may have increased as consequence of the lower MAP
causing tubular ischemia. However, renal excretion of
NGAL and NAGase normalized after the ALM treatment
was discontinued, suggesting that minimal tubular in-
jury occurred. Lower urine output may also be caused
by a downregulation of tubular activity from the effect
of adenosine or the detrimental effects of A3 receptor
activation [50,51].
The 5-hour infusion period is too short to fully eluci-
date the effects of ALM infusion on tubular function,
and future studies over longer times are required for a
full renal assessment including histological evaluation.
Oxygen consumption and delivery
Previous studies in septic patients have demonstrated
that whole body VO2 is increased compared with that inhealthy controls [52]. VO2 increased in the control group
in the present study. In contrast, infusion of ALM main-
tained VO2 at a significantly lower set point than controls,
along with significantly higher oxygen delivery and a
higher arterial–venous oxygen difference. The VO2-lower-
ing effect of ALM disappeared immediately after cessation
of the infusion, indicating that the effect was directly re-
lated to the treatment. This is consistent with a previous
study of porcine hemorrhagic shock in which the combin-
ation of adenosine and lidocaine reduced whole body VO2
by 27% after return of shed blood during resuscitation
[13]. While most clinical trials have failed to improve the
oxygen supply/demand by increasing supply, our study
suggests that an alternative approach may be to use ALM
infusion to lower demand [53,54].
In our study, it is possible that ALM reduced VO2 in
part by blunting the hypermetabolic effects of elevated cat-
echolamine levels via anti-adrenergic receptor modulation
[55-57]. The potential anti-adrenergic effects of ALM may
arise from adenosine’s well-known anti-adrenergic ef-
fect via activation of the A1 receptor [36,58] and mag-
nesium’s effect to inhibit calcium channels at peripheral
sympathetic nerve endings [59]. Further studies are re-
quired to examine this question in vivo. While plasma
lactate levels increased in controls, lactate levels were
consistently lower in the ALM group, consistent with an
improved oxygen supply–demand balance. We recognize
that the small difference in lactate levels may be clinically
irrelevant; however, a recent clinical study demonstrated
that even mild hyperlactatemia, similar to that observed in
controls, was associated with worse outcome in critically
ill patients [60].
Limitations
This experimental porcine study of 5-hour continuous
lipopolysaccharide infusion has several limitations that
may limit its clinical translation. Firstly, continuous lipo-
polysaccharide infusion was chosen because it induces a
rapid, reproducible systemic inflammatory response [18]
and is a relevant model of acute lung injury [23,42]. The
administration of ALM was started concomitant with lipo-
polysaccharide infusion, which does not reflect the clinical
time course of delayed therapy after diagnosis of sepsis.
The time course of lipopolysaccharide-induced immune
activation is more rapid than the more gradual and pro-
longed natural time course in septic patients.
Secondly, clinical translation may be problematic since
live bacteria were not used and the natural time course of
organ failure normally occurs after 5 hours in humans, al-
though recently it was demonstrated that ALM conferred
significant protection in a rat model of cecal ligation and
puncture [16].
Lastly, the hemodynamically stable porcine model
without vascular co-morbidities, such as carotid stenosis
Granfeldt et al. Critical Care  (2014) 18:682 Page 17 of 19and ischemic heart disease, is a model in direct contrast
to the hemodynamically unstable patient suffering from
severe sepsis or septic shock. The presence of vascular
co-morbidities and hemodynamic instability may make
these organs more vulnerable to hypoperfusion second-
ary to hypotension and offset the protective properties
of ALM.
For translation from the current experimental model to
the septic patient, the effect of ALM needs to be examined
in a more clinically relevant model with live bacteria;
hemodynamic instability and prolonged observation times
with survival outcomes are required.Conclusion
The present study demonstrates that treatment with ALM
in an endotoxemic porcine model: reduces leukocyte super-
oxide anion production and TNFα release; induces a state
of reversible hypotension with improved oxygen delivery,
cardiac function and pulmonary function; reduces whole
body VO2; and causes a modest transient drop in renal
function that is reversed after the treatment is stopped.Key messages
 Treatment with ALM induces a fully reversible
stable hypotensive state.
 This hypotensive state is associated with increased
oxygen delivery and heart rate, a decrease in oxygen
consumption and lower lactate levels.
 During hypotension there is decrease in renal
function that is fully reversed after treatment is
turned off.
 Treatment with ALM improves cardiac and
pulmonary function.
 Treatment with ALM attenuates TNFα levels and
leukocyte superoxide anion production.
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